ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Oct 26, 2015
If It Happened to AbbVie, Could It Also Happen to Gilead?
Recent news concerning AbbVie’s hepatitis C drugs caused a severe decline in the company’s share price. Could such an event happen to Gilead?
Jul 28, 2015
Quick Take: Gilead Blows By 2Q Estimates; Investors Getting Drug Pipeline for Free
We continue to like the company that found a way to cure hepatitis C.
Jul 7, 2015
Teva Pharmaceuticals Committed to Acquiring Mylan
Best Ideas Newsletter portfolio holding Teva Pharmaceuticals is committed to creating a generics industry giant. The deal has great potential, but the companies aren’t seeing eye-to-eye.
Jun 16, 2015
Target-CVS Agreement: What It Really Means
Target and CVS recently signed a major partnership, but a Best Ideas Newsletter portfolio holding may benefit the most from the agreement. Let’s take a closer look at effects of the deal.
Feb 20, 2015
10 Bucks per Hour; What It Really Means
Succumbing to political and labor pressure, Walmart sets frightening path of labor costs.
Jan 9, 2015
January 5-9: The Week That Was - Drowning in Crude
Let’s cover new developments during the first week of 2015.
Sep 30, 2014
This Just Feels Different…Mr. Brown
We think the correction is coming. Here are 7 reasons why we plan to reduce exposure to cyclicals and add some protection to the portfolios.
Aug 20, 2014
Walgreen’s and Target Distracted; Dollar General Enters the Fray
Distractions in the executive suite can be painful, but they are not permanent. We expect both Walgreen’s and Target to recover from recent stumbles. The dollar-store industry may be done consolidating for now, but we don’t think tie-ups are completely over.
Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings.
Feb 17, 2014
Deciphering Valuentum’s Dividend Lingo
Let’s examine how some investors are using the framework behind the Valuentum Dividend Cushion, if not the measure itself.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.